Journal article
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
- Abstract:
-
Objectives
Expand abstract
To investigate the safety of ofatumumab retreatment in rheumatoid arthritis.
Methods
Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreatment (700 mg X 2 intravenous infusions two weeks apart) ≥24 weeks following the first course and ≥16 weeks following further courses. Retreatment required evidence of clinical ...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 1.2MB)
-
- Publisher copy:
- 10.1371/journal.pone.0157961
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
GlaxoSmithKline Pharmaceuticals
More from this funder
Genmab
More from this funder
Bibliographic Details
- Publisher:
- Public Library of Science Publisher's website
- Journal:
- PLoS One Journal website
- Volume:
- 11
- Issue:
- 6
- Pages:
- 320-330
- Publication date:
- 2016-06-23
- Acceptance date:
- 2016-06-05
- DOI:
- EISSN:
-
1932-6203
- ISSN:
-
1932-6203
- Source identifiers:
-
656055
Item Description
- Keywords:
- Pubs id:
-
pubs:656055
- UUID:
-
uuid:b767952c-880b-49f3-8dc3-5c8caea843fa
- Local pid:
- pubs:656055
- Deposit date:
- 2016-11-01
Terms of use
- Copyright holder:
- Quattrocchi et al
- Copyright date:
- 2016
- Notes:
- © 2016 Quattrocchi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record